NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today announced that the English version of the Annual report for 2019 is now available on the company’s website, www.neurovive.com.
The Annual report is also attached below.
This information is information that NeuroVive Pharmaceutical is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 2020-04-23 13:00 CEST.
For more information, please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/
Follow us on LinkedIn
Subscribe to our YouTube channel
About Us
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market’s Pink Open market in the US (OTC: NEVPF).